Literature DB >> 9114146

Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor.

C E Gonzalez1, D R Couriel, T J Walsh.   

Abstract

Disseminated zygomycosis in persistently neutropenic patients has been almost uniformly fatal despite aggressive surgical and medical management. We describe a neutropenic patient with disseminated zygomycosis that involved the lungs and kidneys and was successfully treated with amphotericin B lipid complex and granulocyte colony-stimulating factor, followed by suppressive therapy with amphotericin B for 1 year. This approach preserved the patient's renal function and restored systemic host defenses. The single pulmonary lesion was resected, but no resection of renal tissue was attempted because of the bilateral extension of the renal lesions. After a 1-year period of follow-up without antifungal therapy, the patient's condition remains stable, and there has been no relapse of the infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9114146     DOI: 10.1093/clinids/24.2.192

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

1.  Zygomycotic gangrenous cellulitis in a patient with non-insulin dependent diabetes mellitus.

Authors:  O Zimhony; E Israeli; S D Malnick; A Pansky; P Cohen; D Geltner
Journal:  West J Med       Date:  1998-03

Review 2.  Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome.

Authors:  Giuseppe Frasci
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Filgrastim in patients with neutropenia: potential effects on quality of life.

Authors:  Gary H Lyman; Nicole M Kuderer
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

5.  Zygomycosis caused by Rhizopus microsporus and Rhizopus oryzae in Madhya Pradesh (M.P.) Central India: a report of two cases.

Authors:  Shesh R Nawange; S M Singh; J Naidu; S Jain; T Nagpal; D S Behrani; E Mellado; J L Rodriguez Tudela
Journal:  Mycopathologia       Date:  2012-03-23       Impact factor: 2.574

6.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

7.  Mucormycosis in a patient with acute myeloid leukemia successfully treated with liposomal amphotericin B associated with deferasirox and hyperbaric oxygen.

Authors:  Eduardo Flavio Oliveira Ribeiro; Vitorino Modesto dos Santos; Guilherme Teixeira Guimarães Paixão; Leonardo Rodrigues Cruz; Milena Zamian Danilow; Vinicius Ferreira Campos
Journal:  Mycopathologia       Date:  2013-02-27       Impact factor: 2.574

8.  Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.

Authors:  Ashraf S Ibrahim; Valentina Avanessian; Brad Spellberg; John E Edwards
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 9.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

10.  Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice.

Authors:  M Mar Rodríguez; Enrique Calvo; Marçal Mariné; F Javier Pastor; Joan Fernandez-Ballart; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.